RESEARCH PARTICIPANT INFORMED CONSENT FORM
FOR STUDY A

Sponsor / Study Title: Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) / “A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults” ACTIV5/BET

Protocol Number: 20-0013

Principal Investigator: (Study Doctor)

Telephone: 

Address: Brigham and Women's Hospital
Boston, MA 02115

This form is for use in a research study that may involve participants who may or may not have the capacity to consent to take part in the study. When the participant cannot legally consent to take part, pronouns “you” and “your” should be read as referring to the participant rather than the person (legally authorized representative) who is signing and dating this form for the participant. In cases where the participant’s representative gives consent, the participant should be informed about the study to the extent possible given his/her understanding. During the course of the study, if the participant regains the capacity to consent, informed consent will be obtained from the participant and the participant offered the ability to leave the study if desired.

KEY INFORMATION

This consent form describes a clinical research study and is designed to help you decide if you would like to be a part of the study. A clinical research study helps doctors test new ways to treat a disease. One way to do this is by studying new drugs, to see if they could be used as medicines. In a study, the drugs are “experimental,” which means they have not been proven to work. That is why studies are needed to find out if new drugs are safe and work in people.

This section provides the information we believe is most helpful and important to you in making your decision about participating in this study. More information that may help you decide can be found in other sections of the document.
What you should know about this study:

- You are being asked to join this clinical research study because you are currently hospitalized with an illness known as COVID-19 caused by the new coronavirus, SARS CoV-2.
- This study is taking place at more than one site.
- This is a study that will test a series of different drugs, so drugs will be added or removed over time. However, the drugs that are currently being studied at this site are described in this consent.
- Read this consent form carefully or have someone you trust read it to you. Take as much time as you need to understand the study.
- Ask the study team to explain any words or information that you do not understand.
- You are a volunteer and you do not have to join this study. Your other option is to continue receiving any other care you have already been receiving. If you join the study, you can change your mind later. You can decide not to take part, or you can quit at any time. There will be no penalty or loss of benefits if you decide not to join or to quit the study. However, please note that the United States Food and Drug Administration (FDA) requires that any information collected up to the point of your withdrawal cannot be removed from the study.
- The study doctor or the sponsor can stop your participation at any time without your consent for the following reasons:
  - If it appears to be medically harmful to you;
  - If you fail to follow directions for participating in the study;
  - If it is discovered that you do not meet study requirements;
  - If the study is cancelled; or
  - For administrative reasons.
- During the study, we will tell you if we learn any new information that might affect whether you wish to continue to be in the study.
- As a part of this research, we will take blood from you to do genetic testing, which identifies your DNA. DNA is inherited material in your cells that tells us how your body works. We will do these tests to learn how your body responds to COVID-19.

What is this study about?
There are few approved medicines to treat COVID-19 illness. Some people who become sick with COVID-19 have serious disease and must be hospitalized, and a small number of people die. Research studies suggest that a recently approved drug called remdesivir (VEKLURY®) helps hospitalized people with COVID-19 recover faster than people who do not get remdesivir. We want to find out if other drugs given with remdesivir can improve recovery and are safe.

Over time, we will test a series of different drugs, so drugs will be added or removed over time. However, the drugs that are currently being studied at this site are described in this consent.

What drugs are being studied?
This study is designed to test remdesivir in combination with either 1 other study drug or placebo. A placebo is an inactive agent that looks exactly like the study drug but does not have any active drug in it. Using a placebo is common in research studies. It will help us know whether the results of the study are actually caused by the study drug(s).
There may be more than 1 study drug that is available to be combined with remdesivir at a given time. The study drugs currently available to be combined with remdesivir at this site are described below (see Section 3).

**What study drugs will you get?**

Remdesivir is given to all people who enroll in this study. In addition to remdesivir, you will get 1 other study drug (see Section 3) or placebo. What you are assigned to receive in combination with remdesivir is decided by chance, like rolling dice. We will first check your health to see how many of the study drugs would be safe for you to use. Then, you will be assigned to receive one of the study drugs that you are eligible for or placebo. If 1 study drug is being tested at this site, you will have an equal chance of being assigned to the study drug or placebo. If more than 1 study drug is being tested at this site, you will have a higher chance of receiving a study drug than placebo. You can ask someone on the study team if you have any questions about what study drug or placebo you may get.

If you join this study, you will be randomly assigned to a study drug group. We will tell you which study drug group you have been assigned to, however, we cannot tell you if you will receive the actual study drug or placebo. The study doctors will not know this either, but they can find out in case of emergency. This is called a double-blind study, since neither you nor the study doctors know if you got the study drug or placebo.

**What will happen during this study?**

If you agree to join this study, we will first check your health to make sure it is safe for you to join. If you qualify for this study and decide to join, you will get remdesivir once daily for up to 10 days. It is given as an infusion into your bloodstream through an intravenous tube placed in a vein in your arm using a needle (IV line). You will also receive 1 other study drug or placebo, depending on your study drug assignment. More information about the study drugs and how they are given is provided below.

While you are in the hospital, we will collect information from your hospital records. We will take one or more blood sample(s) and one swab (throughout this form swab collections can mean swabs can be collected from deep inside your nose, the middle of your nose, or your throat) from you about 5 times, depending on how long you remain in the hospital.

You will have up to 5 follow-up study visits after you leave the hospital. The exact number will depend on when you are discharged. At least 3 follow-up visits will be conducted over the phone. The others may be in-person visits at the study site or may be conducted over the phone. During follow-up visits, we will collect information about your health since your last visit. For in-person visits, we will also take one or more blood sample(s) and one swab.

We will use the blood and swab samples collected on this study for research and safety tests. Swab samples will be tested for SARS-CoV-2.

Your total amount of time on this study will be about 2 months.
What are the main study risks?
The main risks of being in this study are related to the study drugs. The study drug remdesivir has been studied in healthy (not sick) people and in people with COVID-19 or other viral infections. Some of these people had side effects which were temporary and went away after a few days. Some people did not have side effects. The most common side effects included abnormal liver function test results, abnormal blood clotting test results, constipation, nausea, vomiting, decreased appetite, headache, and pain or infection around the IV line. The abnormal liver function tests lasted longer than a few days but came back to normal levels during the studies.

Risks of the other study drugs currently being tested at this site are given below (See Section 3).

Some people may have some side effects from the study drugs. Other people may have no side effects. Allergic reactions to these drugs, including hives, trouble breathing, or other allergic responses are very rare but are a possible effect of any drug. Allergic reactions may be severe or life-threatening. There may also be side effects and risks that we do not know about yet, even serious or life-threatening ones. We will watch you carefully for side effects during this study. We will provide short-term medical care if there are side effects from the study drugs that can be treated.

If you are pregnant or nursing a child during the study, there may be risks to you, the embryo, fetus, or nursing child from the study drugs. Therefore, you cannot join this study if you are pregnant or breastfeeding. If you are nursing a child, you must agree to discontinue breastfeeding while on this study. If you can become pregnant, you must agree to remain abstinent (not having sexual relations) or use contraception. If a hormonal method of contraception is used (for example, an implant, a hormone-releasing intrauterine device [IUD], injections, pills, a vaginal ring, or a skin patch) a barrier method must also be used at the same time (for example, male condom, diaphragm, cervical cap) while taking part in this study and for 5 months after your last dose of the study drug or placebo. Please speak to the study doctor or study staff about acceptable methods of birth control.

Are there benefits to being in the study?
You may or may not benefit from being in this study. Results from studies suggest that your time in the hospital may be shorter by taking remdesivir. Everyone in this study receives remdesivir.

What are your other options?
You do not have to join this study if you do not want to. You can keep getting treated with standard care for COVID-19, which may include treatment with remdesivir.

There might be other clinical trials that you can join for experimental treatments for COVID-19. However, you cannot participate in this study and other clinical trials for experimental treatments for COVID-19 at the same time.
The rest of this document will describe more about the research study. This information should be considered before you make your choice. Members of the study team will talk with you about the information described in this document.

1. **What will happen if you want to join this study?**

If you think you may want to join this study, we will describe the study and answer any questions you may have. You can also talk to your friends and family about the study.

If you agree to be in the study, we will ask you or your Legally Authorized Representative (LAR) to sign and date this consent form. When you sign your name or put your mark on the consent form and date it, it means that you agree to be in the study. You can change your mind at any time and leave the study. If you decide not to join the study or to leave the study later, you will not lose any regular health care services you already are getting. Approximately 200 hospitalized adults with COVID-19 will be asked to participate in each stage of this study.

To determine if you qualify for this study, we will ask you some questions about your health, including any chronic medical conditions and medications you take for them, allergies to medications, any COVID-19 symptoms you have had, and which medications you received from your regular doctor during this COVID-19 illness. We will perform a physical exam and measure your height and weight. We will review your hospital records for the result(s) of your SARS-CoV-2 test and any X-rays or CT scans you have had during this COVID-19 illness, and may also collect some of the other information listed above, such as COVID-19 symptoms, medications, etc. If you have had blood tests done within the past 48 hours to check how well your liver and kidneys are working, we will review the results of these tests in your hospital records; otherwise, we will collect a blood sample to do these tests. If you are a woman who is capable of getting pregnant, we will do a pregnancy (urine or blood) test. A member of the study team will explain these tests further. When we have the results, we will explain them to you.

2. **What does the study involve?**

If you qualify for the study and decide to join, you will get up to 10 days of remdesivir while you are in the hospital. You will also receive another study drug or placebo, depending on which one you were assigned to, also only while you are in the hospital. More information about the study drugs, how they are given, and their risks is provided below in Section 3. After you are discharged from the hospital, you will not receive any more study drugs. If you are readmitted to the hospital before Day 11, you may receive the rest of your remdesivir infusions, up to Day 10.

Each day you are in the hospital, we will obtain some information about you from your inpatient hospital records, such as whether you are receiving oxygen or need additional help breathing and what types of other medicines you are being given as part of your clinical care. This information will help us determine how sick you are and whether you are improving. We will take one or more blood sample(s) and one swab from you on Days 1, 3, 5, 8, and 11 as long as you remain in the hospital.
You will have follow-up visits on Days 8 (if you have already been discharged from the hospital), 15, 22, 29 and 60. The Day 15 and Day 29 visits will be in-person visits, if possible. If you have already been discharged from the hospital at these timepoints, we may ask you to come back to the site for these visits. However, if this is not possible due to quarantine restrictions or similar reasons, we will call you to collect information over the phone. All Day 8, Day 22, and Day 60 visits will be conducted over the phone (if you have already been discharged). For all follow-up visits (both in-person and by telephone), we will ask how you are feeling and if you have been sick. If you were already discharged, we will ask if you had any additional hospital stays or clinic visits or needed additional treatments or medicines since your discharge. If you have in-person visits on Days 15 and 29, we will also take one or more blood sample(s) and one swab.

The total amount of blood that we will collect from you for this study is up to about 31 tablespoons. We will use the blood samples and swabs collected on this study for research and safety tests. Swabs will be tested for SARS-CoV-2. Swabs will be collected from deep in your nose. If this is not possible, the swab will be taken from the middle or front of your nose or throat.

As part of this study, we will collect some extra blood samples from you (included in the total amount given above) that we do not need for our current study goals. We will use your coded information, leftover samples, and extra blood samples collected during your participation on this study for secondary research. Secondary research is research that is not part of this study, and the research is not planned yet. This research will occur in the future and it will help us to understand how the study drugs work and to develop new treatments and lab tests. This secondary research will not include genetic testing. More information about secondary research is provided below.

The last visit for this study is at Day 60. Your study participation will be complete after this visit. Your total amount of time on this study will be about 60 days.

3. What are the study drugs and their risks?

Remdesivir

**Description:** Remdesivir is an antiviral drug that blocks viruses like SARS-CoV-2 from replicating, or reproducing. The United States Food and Drug Administration (FDA) recently approved remdesivir as a treatment for COVID-19, which means it can be given to COVID-19 patients as standard treatment.

Remdesivir is given as an infusion into your bloodstream through an intravenous tube placed in a vein in your arm using a needle (IV line). It is given once daily for up to 10 days. Each dose takes about 30 minutes to give, but could take up to 2 hours.

**Risks:** The most common side effects seen in people who received remdesivir in research studies included:

- Abnormal liver function test results
- Abnormal blood clotting test results
- Constipation
- Nausea
- Vomiting
- Headache
- Dizziness
- Pain or infection around the IV line

The abnormal liver function tests lasted longer than a few days but came back to normal levels during the studies. We have not seen any long-lasting kidney problems in humans who have taken remdesivir. We will be following your liver and kidney function during the study. If you have any abnormal test results that may require medical care, we will share these results with you.

In previous study with participants hospitalized with COVID-19, the most common adverse events included:

- Decreased renal function
- Decreased hemoglobin (anemia)
- Decreased lymphocyte count
- Respiratory failure
- Fever
- Increased blood glucose

The occurrence of these adverse events were similar in the remdesivir and placebo groups.

None of the side effects in studies of remdesivir have been serious. Some people may have some side effects after the infusion. Other people may have no side effects. These side effects are temporary and should not last more than a few days.

We will monitor you closely for side effects while you are getting remdesivir. We will have medicine and equipment available to treat any side effects, including severe effects, if needed. If you have severe side effects that do not get better, we will not give you any more doses of remdesivir.

**Risankizumab**

*Description:* Risankizumab is a drug that is approved by the FDA to treat a condition called plaque psoriasis. It is a type of drug called a monoclonal antibody, and it works by attaching to natural proteins in the body that can cause inflammation. It ultimately reduces inflammation inside the body. Because inflammation seems to be one of the most serious problems during COVID-19 illness, we think that this drug may helpful. Risankizumab is not approved by the FDA to treat COVID-19, but they have given us permission to test it in this study.

Risankizumab is given as an infusion into your bloodstream through an intravenous tube placed in a vein in your arm using a needle (IV line). It is given once and the infusion takes about 1 to 2 hours.

*Risks:* The most common side effects seen in people receiving risankizumab include:

- Upper respiratory infection
• Fungal skin infection
• Headache
• Tiredness

Because of the way risankizumab works, it may increase the risk of serious infections, such as a bacterial skin infection (cellulitis), infection of a bone (osteomyelitis), herpes zoster infection, or others. However, the chance that this would happen with the single infusion of risankizumab that is being given in this study is very low.

Risankizumab can cause an allergic reaction, which may include fever, chills, nausea, hives, itching, decreased blood pressure, swelling, decreased oxygen supply, wheezing, difficulty breathing, and an abnormal heartbeat. Severe allergic reactions (called anaphylaxis) can cause heart attacks and, if untreated, even death. We cannot always predict in advance who might develop this serious reaction.

We will monitor you closely for side effects while you are getting the risankizumab and will have medicine and equipment available to treat side effects, including severe effects, if needed. If you have a severe side effect that does not improve with treatment, we will stop the infusion.

**Placebo**

*Description:* The placebo for this study is an inactive liquid that is similar to risankizumab, but does not have any active drug in it. It is given once as an IV infusion that takes about 1 to 2 hours.

*Risks:* The main risks of a placebo infusion are those associated with IV line placement described below (see Section 4).

**4. What are the other risks or discomforts of the study?**

**General study drug risks**

Since these are new drugs that we are still studying, they may cause other changes that could hurt or bother you that we do not know about. People can have allergic reactions to drugs, including hives, trouble breathing, or other allergic responses. This is very rare but is also a possible effect of any drug. Allergic reactions may be severe or life-threatening.

Short-term medical care will be provided if there are side effects from the study drugs that can be treated. It is important that you always tell the study staff if you have any problems and always keep in touch with them.

**Blood draws and IV line placement**

We will insert a new, clean needle into a vein in your arm to take blood samples and to insert the IV line. If you already have an IV line, the blood samples can be taken from that. You may feel a pinch when the needle goes through your skin. A bruise may appear where it was put in. You may also have swelling, and the area may be sore. These things are common and should go away in a couple of days. Drawing blood may cause brief discomfort and fainting. Fainting is usually for a short period and would be managed by having you lie down and elevate his/her legs. There
is a very small chance of an infection where you have the tube in your arm. An infection could be treated with antibiotics.

**Swab collection**

*Throat swab:* This procedure may be uncomfortable, and it causes many people to gag.

*Middle nose swab:* This procedure may tickle and be slightly uncomfortable.

*Deep nose swab:* Most people feel pressure and discomfort during this procedure, and it can cause a nosebleed.

**Confidentiality risks**

We will be careful to keep your study information confidential, but there is a small risk that someone not involved in the study could get this information.

**Partners Alert System**

Partners has an electronic system that lets your study doctors know if you are admitted to a Partners hospital, or if you visit a Partners hospital Emergency Department. Partners hospitals want to make sure the study doctors know about any possible problems or side effects you experience while you are taking part in the study. If you obtain emergency medical care at another hospital or clinic, please let your study doctor or study staff know as soon as possible.

**Study Information Included in Your Electronic Medical Record**

A notation that you are taking part in this research study may be made in your electronic medical record. Information from the research that relates to your general medical care may be included in the record (for example: list of allergies, results of standard blood tests done at the hospital labs).

**Genetic Testing:**

As stated above, we will perform genetic testing on your blood sample. This genetic testing will focus on COVID-19 and provide information about how your body responds to the disease. Following genetic testing, and with your consent, your genetic testing information may be shared. A summary of the genetic results from all participants in this study can be placed in a public, unrestricted open access database that anyone can freely use. No individual genetic testing information or results will be placed in an open access database. The risk of anyone identifying you with this information is very unlikely.

Since your genetic data and health information may be stored and shared with other researchers, there may be a risk that information resulting from research genetic testing could be misused for discriminatory purposes.

A federal law, called the Genetic Information Nondiscrimination Act (GINA), generally makes it illegal for health insurance companies, group health plans and most employers to discriminate against you based on your genetic information.

This law generally will protect you in the following ways:
• Health insurance companies and group health plans may not request your genetic information that the sponsor will get from this research.

• Health insurance companies and group health plans may not use your genetic information when making decisions regarding your eligibility or premiums.

• Employers with 15 or more employees may not use your genetic information that the sponsor will get from this research when making a decision to hire, promote, or fire you or when setting the terms of your employment. The Sponsor will generally not provide this information to others without your consent. Your study site also has to follow privacy laws to protect your information.

All health insurance companies and group health plans and all employers with 15 or more people must follow this law.

Be aware that this Federal law does not protect you against genetic discrimination by companies that sell life insurance, disability insurance or long-term care insurance.

If you have any questions, please ask your study doctor. Researchers who will have access to genetic information about you will take measures to maintain the confidentiality of your information.

Please initial your decision for us to use your information and samples for genetic research for this research study:

______ YES, you may use my information and samples for genetic research.

______ NO, you may not use my information and samples for genetic research.

Risks to pregnancy and nursing children
If you are pregnant or nursing a child during the study, there may be risks to you, the embryo, fetus, or nursing child from the study drugs. If you are nursing a child, you must agree to discontinue breastfeeding while on this study. If you can get pregnant, you must agree to remain abstinent or use birth control while you are on this study and for 5 months after your last dose of the study drug or placebo. A member of the study team will talk with you about acceptable forms of birth control. You should not participate in this study if you can become pregnant and cannot use one of these birth control methods. Some methods of birth control will not work when you are taking certain drugs. Be aware that women can still become pregnant even if using an acceptable birth control method.

If you think or know you have become pregnant during the study, please contact the research team member. You will not receive any more study drug. The team will ask your permission to follow-up with you about your health and the health of your baby until delivery.
5. **Are there benefits to being in the study?**

You may or may not benefit from being in this study. Your participation in this study is important to learn more about the study drugs if they are safe and work in hospitalized participants with COVID-19.

6. **What instructions do you need to follow?**

You should not drink any alcohol for 14 days after you start receiving the study drug on Day 1. If you feel that you need other medicines or herbal products, you should talk to a member of the study team first.

If you are nursing a child, you must agree to discontinue breastfeeding while on this study. If you can get pregnant, you must agree to remain abstinent or use birth control while you are on this study and for 5 months after your last dose of the study drug or placebo.

You may not volunteer for another study that gives participants a new study drug for COVID-19 for at least 29 days after you start receiving the study drug on Day 1. If you want to be in another study that follows people who have or have had COVID-19, you should talk to a member of the study team first, especially if the other study involves blood collection.

7. **What other choices do you have?**

Before you decide whether to be in this study, we will discuss other options that are available to you. Instead of being in this study, you could look for other studies of experimental drugs for COVID-19. You can also continue to receive regular supportive hospital care for patients with COVID-19 instead of joining a research study. This could include treatment with remdesivir.

8. **Will new findings be shared with you?**

If we find out any new information that may affect your choice to participate in this study, we will contact you to explain what we have learned. This may be information we have learned while doing this study or information we have learned from other scientists doing similar research in other places.

We are doing genetic testing (sequencing) for research purposes and not to look for inherited disease or defects; therefore, we will not return results from sequencing.

9. **What will happen to your samples and personal information?**

We will store your samples and data (information) until we are able to test all samples for SARS-CoV-2. Your stored samples and data will be marked with a code and not with your name. Only researchers linked to this study can get the codes.
Your study information will be placed in a secure electronic system. It will not include your name. This information cannot be traced back to you. Your samples will not be sold. You will not be paid for any products that result from this research.

The only risk of allowing us to store your samples would be an accidental release of your identity.

Some of the blood collected for this study may not be needed to do the research tests. We plan to store and use these leftover samples along with your information (identified only by ID codes) for secondary research. Secondary research is research that is not part of this study but will be performed in the future. You will not be told about the future research. Also, we will collect extra blood samples (about 3 teaspoons when other blood is drawn) to store and use for secondary research. Secondary research may help us understand how remdesivir and the other study drugs work, study other infections or diseases, or develop other treatments. The types of research may include development of new laboratory tests to better understand responses to infection or for studies to better understand virus infections, including SARS-CoV-2 infection.

You may change your mind about secondary research and withdraw consent for the storage and use of your coded samples or information at any time. You will need to contact the study doctor using the contact information listed on page 1 of this form. We will do our best to follow your wishes but cannot promise that we will always be able to destroy your samples or data. For example, if your samples were already used, we would not be able to destroy them.

Please initial your decision about permission for us to use your excess/leftover blood samples for future research:

______ YES, you may collect and store my excess/leftover blood samples for an indefinite period of time and use them for future research.

______ NO, you may not store my excess/leftover blood samples for an indefinite period of time and use them for future research. I understand that by saying NO, I can still take part in this study.

10. What do you need to do for follow-up on this study?

If you feel sick at any time during the study, it is important that you quickly tell the study team at the hospital (if you are still hospitalized) or call the study contact number you were given when you left the hospital (if you have been discharged). We may ask you to return to the study site for a medical exam and possible sampling.

11. What will I have to pay for if I take part in this study?

It will not cost you anything to be in this study.

Study funds will pay for certain study-related items and services that are being done only for research. However, we may bill your health insurer for, among other things, routine items and
services you would have received even if you did not take part in the research. You will be responsible for payment of any deductibles and co-payments required by your insurer for this routine care or other billed care.

If you have any questions about costs to you that may result from taking part in the research, please speak with the study doctors and study staff. If necessary, we will arrange for you to speak with someone in Patient Financial Services about these costs. **Before you agree to be in this study, you should contact your health insurer to see if your plan will cover the costs required as part of your participation.**

12. **Will you be paid if you join this study?**

You will not receive any monetary compensation for your participation in this study.

13. **Who is watching over this study?**

A Data and Safety Monitoring Board (DSMB) will be looking at the study information very closely. The DSMB is made up of doctors and other people who are not directly involved in the study and who have a good understanding of severe coronavirus infections and research studies. The DSMB may recommend changing the study or stopping the study earlier than planned if they think it is not safe to continue. The National Institutes of Health (NIH), local ethics and health authorities, and the U.S. FDA will also be watching over this study and have the authority to stop the study at any time.

14. **How will your privacy be protected?**

We will keep your study information private. All files with information that could identify you will be kept in locked cabinets or secure password protected computers. People responsible for making sure that the research is done properly may look at your study records. This might include people involved in this study from this hospital and the U.S. government including the NIH and their designees and the U.S. Food and Drug Administration, the Institutional Review Board (Advarra IRB), and the drug companies that make the study drugs (remdesivir by Gilead Sciences, Inc., and risankizumab by AbbVie Inc.). All of these people will also keep your identity private. By signing and dating this consent form, you agree that results from this study, but not your identity, may be shared with local medical providers, makers of the study drugs, or government health organizations to help them better understand COVID-19. When results of an NIH research study are reported in medical journals or at scientific meetings, the participants who take part in the study are not named or identified.

To help us protect your privacy, we have a Certificate of Confidentiality (Certificate) from the NIH. Study staff cannot provide to any person not connected with the research your name, or any materials that contain identifiable, sensitive information about you, unless permitted or required by a legal exception, such as state laws that require reporting of some contagious diseases. The most important protection provided by the Certificate is that the study staff cannot be forced to provide any of your identifiable, sensitive information, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, such as if there is a court subpoena,
without your permission. The study team will use the Certificate to resist any demands for information that would identify you.

Your information protected by the Certificate may still be disclosed or used when the information:

1. Is disclosed to people connected with the research, for example, information may be used for program evaluation internally by the NIH; or
2. Is required to be disclosed by Federal, State, or local laws, for example, when information must be disclosed to meet the legal requirements of the federal U.S. FDA;
3. Is necessary for your medical treatment and you have consented to this disclosure;
4. Is for other research;
5. Is disclosed with your consent (for example, an insurer or medical care provider gets your written consent for us to disclose the research information).

The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or others including, for example, child abuse and neglect, and by signing and dating below you consent to those disclosures.

15. Will the study require any of your other health care providers to share your health information with the researchers of this study?

As a part of this study, the researchers may ask to see your health care records from your other health care providers. You will be asked to give us a list of other health care providers that you use.

To do this research, we will need to collect, use, and share your private health information. Your private information may include things learned from the procedures described in this consent form, as well as information from your medical record.

If I take part in this research study, how will you protect my privacy?

During this research, identifiable information about your health will be collected. In the rest of this section, we (Partners Hospitals) refer to this information simply as “health information”. Under federal law, health information is private. However, there are exceptions to this rule, and you should know who may be able to see, use, and share your health information for research and why they may need to do so.

In this study, we may collect health information about you from:

- Past, present, and future medical records
- Research procedures, including research office visits, tests, interviews, and questionnaires

Who may see, use, and share your identifiable health information and why they may need to do so:

- Partners research staff involved in this study in order to conduct the research
- The sponsor(s) of this study, and the people or groups it hires to help perform this research or audit the research
• Other researchers and medical centers that are part of this study and their ethics boards
• A group that oversees the data (study information) and safety of this research
• Non-research staff within Partners who need this information to do their jobs (such as for treatment, payment (billing), or health care operations)
• Advarra IRB Review a group of people who review research studies to protect the rights and safety of research participants
• People from organizations that provide independent accreditation and oversight of hospitals and research
• People or groups that we hire to do work for us, such as data storage companies, insurers, and lawyers
• Federal and state agencies (such as the Food and Drug Administration (FDA), the Department of Health and Human Services, the National Institutes of Health, and other US or foreign government bodies that oversee or review research)
• Public health and safety authorities (for example, if we learn information that could mean harm to you or others, we may need to report this, as required by law)

Some people or groups who get your health information might not have to follow the same privacy rules that we follow and might use or share your health information without your permission in ways that are not described in this form. For example, we understand that the sponsor of this study may use your health information to perform additional research on various products or conditions, to obtain regulatory approval of its products, to propose new products, and to oversee and improve its products’ performance. We share your health information only when we must, and we ask anyone who receives it from us to take measures to protect your privacy. The sponsor has agreed that it will not contact you without your permission and will not use or share your information for any mailing or marketing list. However, once your information is shared outside Partners, we cannot control all the ways that others use or share it and cannot promise that it will remain private.

Because research is an ongoing process, we cannot give you an exact date when we will either destroy or stop using or sharing your health information. Your permission to use and share your identifiable information does not expire.

The results of this research study may be published in a medical book or journal, or used to teach others. However, your name or other identifying information will not be used for these purposes without your specific permission.

**Your Privacy Rights**
You have the right **not** to sign and date this form that allows us to use and share your health information for research; however, if you don’t sign and date it, you can’t take part in this research study.

You have the right to withdraw your permission for us to use or share your health information for this research study. If you want to withdraw your permission, you must notify the person in charge of this research study in writing at the address listed on the first page of this form. Once permission is withdrawn, you cannot continue to take part in the study.
If you withdraw your permission, we will not be able to take back information that has already been used or shared with others.

You have the right to see and get a copy of your health information that is used or shared for treatment or for payment. To ask for this information, please contact the person in charge of this research study, listed on page 1 of this form. You may only get such information after the research is finished.

16. What other things should you know about this research study?

A. ClinicalTrials.gov

A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

B. Conflict of Interest

The policy of the NIH is to evaluate investigators at least yearly for any conflicts of interest. This process is detailed in a Conflict of Interest (COI) Guide. You may ask your study team for a copy of the COI Guide or for more information. This study has investigators that are NIH employees and some that are not. All non-NIH investigators are required to follow the principles outlined in the COI Guide but they are not required to report their specific financial holdings to the NIH.

Gilead Sciences, Inc., the company that makes remdesivir, is providing remdesivir for this study to NIH without charge. AbbVie Inc., the company that makes risankizumab, is providing risankizumab for this study to NIH without charge. No NIH investigator involved in this study receives payments or other benefits from any company whose drug, product or device is being tested. However, there are some research partners not associated with the NIH working on this study who may receive payments or benefits, limited by the rules of their workplace.

C. Whom to Contact About This Study?

During the study, if you experience any medical problems, suffer a research-related injury, or have questions, concerns or complaints about the study, please contact the study doctor at the telephone number listed on the first page of this consent document. If you seek emergency care, or hospitalization is required, alert the treating physician that you are participating in this research study.

An IRB is an independent committee established to help protect the rights of research participants. If you have any questions about your rights as a research participant, and/or concerns or complaints regarding this research study, contact:
• By mail:
  Study Subject Adviser
  Advarra IRB
  6940 Columbia Gateway Drive, Suite 110
  Columbia, MD 21046
• or call toll free: 877-992-4724
• or by email: adviser@advarra.com

Please reference the following number when contacting the Study Subject Adviser:
Pro00046406.

D. What happens if I am injured as a result of taking part in this research study?

We (Partners hospitals) will offer you the care needed to treat any injury that results from
taking part in this research study. We reserve the right to bill your insurance company or
other third parties, if appropriate, for the care you get for the injury. We will try to have
these costs paid for, but you may still be responsible for some of them. For example, if the
care is billed to your insurer, you will be responsible for payment of any of deductibles and
co-payments required by your insurer. To ask questions about this, talk to the study doctor or
study staff. Be aware that your health care payer/insurer might not cover the costs of
study-related injuries or illnesses.

Injuries sometimes happen even when no one is at fault. There are no plans to pay you or
give you other compensation for an injury, should one occur. However, you are not giving
up any of your legal rights by signing and dating this form. If you think you have been
injured or have experienced a medical problem as a result of taking part in this research
study, tell the person in charge of this study as soon as possible. The researcher's name and
phone number are listed on the first page of this consent form.

In general, no long-term medical care or financial compensation for research-related injuries
will be provided by the NIH or the Federal Government.

A Declaration under the Public Readiness and Emergency Preparedness (PREP) Act was
issued by the Secretary of the United States Department of Health and Human Services on
March 10, 2020. This Declaration limits the legal rights of a subject participating in clinical
studies utilizing COVID-19 countermeasures. Because this study is covered by the Prep Act
Declaration, covered persons, such as the manufacturers, study sponsor, researchers,
healthcare providers and others have liability immunity (that is, they cannot be sued by you
or your family under the laws of the United States).

If you believe that you may have been harmed as a result of this research study, certain
claims for serious injury or death caused by the countermeasure may be eligible for
compensation through the Countermeasures Injury Compensation Program. This is a
program set up by the United States Government.
Information about this program can be found at https://www.hrsa.gov/cicp/about/index.html or by calling 1-855-266-2427. If you are eligible for this program, you must file a claim within one year of the administration or use of the covered countermeasure.

Informed Consent and Authorization

Statement of Person Giving Informed Consent and Authorization

- I have read this consent form.
- This research study has been explained to me, including risks and possible benefits (if any), other possible treatments or procedures, and other important things about the study.
- I have had the opportunity to ask questions.
- I understand the information given to me.
- By signing and dating this form, I do not give up any of my legal rights.
- I will get a signed and dated copy of this consent form.

Signature of Subject:

I give my consent to take part in this research study and agree to allow my health information to be used and shared as described above.

______________________________
Printed Name of Subject

______________________________    ______________________________
Signature of Subject                      Date/Time

Statement of Study Doctor or Person Obtaining Consent:

- I have explained the research to the study subject.
- I have answered all questions about this research study to the best of my ability.

______________________________
Printed Name of Person Obtaining Consent

______________________________    ______________________________
Signature of Person Obtaining Consent    Date/Time
Signature of Authorized Representative for Adult:
I give my consent for the person I am authorized to represent to take part in this research study and agree to allow his/her health information to be used and shared as described above.

Print Name (check applicable box below)
☐ Court-appointed Guardian
☐ Health Care Proxy
☐ Durable Power of Attorney
☐ Family Member/Next-of-Kin

Signature ________________________________ Date/Time ________________

If Family Member or Next-of-Kin, Describe Relationship to Subject: ____________________

Adult Assent
Signature of Assenting Adult:
I agree to take part in this research study and agree to allow my health information to be used and shared as described above.

Printed Name of Assenting Adult ________________________________

Signature of Assenting Adult ________________________________ Date/Time ________________

Statement of Witness:
I represent that the consent form was presented orally to the subject in the subject’s own language, that the subject was given the opportunity to ask questions, and that the subject has indicated his/her consent and authorization for participation by (check one box as applicable):
☐ Making his/her mark above
☐ Other means _____________________________________________ (fill in above)

Printed Name of Witness ________________________________

Signature of Witness ________________________________ Date/Time ________________